SAHPRA MedSafetyWeek campaign: Reporting of Side Effects

By HEOR Staff Writer

November 11, 2023

SAHPRA MedSafetyWeek campaign

The Importance of Documenting Side Effects

The South African Health Products Regulatory Authority (SAHPRA) is advocating for the usage of the MedSafety app as a means of bolstering efforts to ensure the integrity of medicinal products. #MedSafetyWeek is a global campaign that aims to improve the safety of medications all around the world, and this project is a component of that campaign. The campaign, involving more than 80 regulatory agencies, is a testament to the collective effort to better the healthcare industry.

 

SAHPRA MedSafetyWeek campaign: A Tool for Safer Medicines

Patients, physicians, nurses, and pharmacists are all able to report adverse effects with the help of a powerful tool called the MedSafety app. These reports are absolutely necessary for the continuous monitoring of the medications’ safety. According to Mafora Matlala, the Pharmacovigilance Manager at SAHPRA, “Every report is important in building more knowledge and understanding of the benefits and risks of medicines in clinical use and allows action to be taken to minimise risks.”

Users can download the MedSafety app from the Google Play Store or the Apple App Store, depending on your device. The app allows users to report adverse events and product quality issues. This helps enhance the safety of the healthcare environment overall.

SAHPRA’s commitment to the safety, efficacy, and quality of all health products underlines its ethos. Together, we can make a difference in ensuring safer medicines for all.

Reference url

Recent Posts

CAPVAXIVE Pediatric Vaccine Approval
Advancing CAPVAXIVE Pediatric Vaccine Approval for High-Risk Youth

By João L. Carapinha

June 19, 2026

The CAPVAXIVE Pediatric Vaccine Approval expands options for children and adolescents aged 2 through 17 who have completed their primary pediatric pneumococcal series yet face elevated risk due to chronic conditions such as diabetes, heart disease, kidney disease, liver disease, or lung disease. ...
USTR Germany Pharma Investigation
USTR Germany Pharma Investigation and its Impact on Global Drug Pricing

By João L. Carapinha

June 19, 2026

The USTR Germany Pharma Investigation has exposed how Germany’s pharmaceutical reimbursement policies force American patients to finance a disproportionately large share of worldwide drug research and development. By systematically suppressing prices below sustainable levels, these practices erod...
Biotechnology Act Europe
Biotechnology Act Europe Driving Innovation and Investment in Life Sciences

By João L. Carapinha

June 18, 2026

The Biotechnology Act Europe offers a once-in-a-generation chance to turn the continent’s world-class life sciences research into scalable commercial successes that remain in Europe rather than migrating elsewhere. By tackling regulatory fragmentation and sharpening investment signals, the legisl...